Get the Stockscreener App
6.03
14.64%
0.77
After Hours:
6.25
0.22
+3.65%
Atyr Pharma Inc stock is traded at $6.03, with a volume of 16.49M.
It is up +14.64% in the last 24 hours and up +15.30% over the past month.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
See More
Previous Close:
$5.26
Open:
$5.27
24h Volume:
16.49M
Relative Volume:
3.68
Market Cap:
$590.86M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+7.49%
1M Performance:
+15.30%
6M Performance:
+69.86%
1Y Performance:
+222.46%
1-Day Range:
$5.22
$6.50
1-Week Range:
$5.08
$6.50
52-Week Range:
$1.67
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
Name
Atyr Pharma Inc
Sector
Industry
Phone
(858) 731-8389
Address
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Compare ATYR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
6.03 | 513.45M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-25 | Initiated | Leerink Partners | Outperform |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-04-24 | Initiated | Wells Fargo | Overweight |
| Sep-05-24 | Initiated | Jefferies | Buy |
| Jul-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-12-21 | Initiated | RBC Capital Mkts | Outperform |
| Sep-21-21 | Initiated | Piper Sandler | Overweight |
| May-10-21 | Initiated | Laidlaw | Buy |
| Aug-17-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-04-20 | Initiated | ROTH Capital | Buy |
| Mar-02-20 | Initiated | Oppenheimer | Outperform |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-07-17 | Initiated | Piper Jaffray | Overweight |
| Dec-13-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-16-15 | Initiated | Citigroup | Neutral |
| Jun-01-15 | Initiated | Citigroup | Buy |
| Jun-01-15 | Initiated | JP Morgan | Overweight |
View All
Atyr Pharma Inc Stock (ATYR) Latest News
American Century Companies Inc. Sells 65,409 Shares of aTyr Pharma, Inc. $ATYR - MarketBeat
Cantor Fitzgerald reiterates Overweight rating on aTyr Pharma stock - Investing.com
aTyr Pharma, Inc. (NASDAQ:ATYR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
1 Small-Cap Biotech Stock Poised for a Breakout - AOL.com
Octagon Capital Advisors LP Acquires 2,652,000 Shares of aTyr Pharma, Inc. $ATYR - MarketBeat
Lead Therapy Trial Fuels aTyr Pharma’s (ATYR) Promising Upside, Leerink Stays Bullish - Yahoo Finance
Can aTyr Pharma Inc. weather a recessionDip Buying & Safe Entry Point Identification - Lancaster City Council
aTyr Pharma Inc put volume heavy and directionally bearish - TipRanks
Is Summit Therapeutics a Buy, Sell, or Hold Now? - AOL.com
Investors Purchase Large Volume of aTyr Pharma Put Options (NASDAQ:ATYR) - MarketBeat
Jefferies Raises Price Target for aTyr Pharma (ATYR) Ahead of Study Results - MSN
aTyr Pharma (NASDAQ:ATYR) Trading Up 8.1%Should You Buy? - MarketBeat
Multi asset correlation models including aTyr Pharma Inc.Weekly Risk Summary & Growth Focused Stock Reports - Newser
When is the best time to exit aTyr Pharma Inc.July 2025 News Drivers & Consistent Growth Stock Picks - Newser
168,742 Shares in aTyr Pharma, Inc. $ATYR Acquired by Wellington Management Group LLP - MarketBeat
How a Surge in Bearish Options Activity at aTyr Pharma (ATYR) Has Changed Its Investment Story - simplywall.st
Does aTyr Pharma Inc. qualify in momentum factor screeningMarket Movement Recap & Step-by-Step Trade Execution Guides - Newser
aTyr Pharma Inc. stock daily chart insightsEarnings Risk Summary & High Accuracy Trade Signal Alerts - Newser
Price momentum metrics for aTyr Pharma Inc. explainedEarnings Performance Report & AI Powered Market Entry Strategies - Newser
Is aTyr Pharma Inc. a play on infrastructure spendingJuly 2025 Outlook & Fast Moving Stock Trade Plans - خودرو بانک
Employee Equity Incentives and Biotech Valuation: How aTyr Pharma’s Inducement Grants Align with Pipeline Progress - AInvest
Is aTyr Pharma Inc. forming bullish engulfing patternsMarket Sentiment Review & Precise Trade Entry Recommendations - خودرو بانک
What is aTyr Pharma Inc.’s book value per shareQuarterly Trade Report & Fast Momentum Stock Entry Tips - خودرو بانک
We're Hopeful That ATyr Pharma (NASDAQ:ATYR) Will Use Its Cash Wisely - 富途牛牛
Using AI based signals to follow aTyr Pharma Inc.Global Markets & High Accuracy Swing Entry Alerts - Newser
Published on: 2025-09-06 02:07:40 - خودرو بانک
ATyr Pharma's Strategic Talent Retention and Pipeline Momentum Signal Long-Term Value Creation - AInvest
ATyr Pharma announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ATYR Stock News - GuruFocus
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biotech aTyr Pharma Awards 62,400 Shares to New Employees for Novel tRNA Drug Development Program - Stock Titan
Is aTyr Pharma Inc.’s ROE strong enough2025 Market WrapUp & Safe Entry Trade Reports - خودرو بانک
Can aTyr Pharma Inc. rally from current levels2025 Key Highlights & Weekly High Return Opportunities - Newser
Tick level data insight on aTyr Pharma Inc. volatility2025 Trade Ideas & Real-Time Chart Breakout Alerts - Newser
Block Trades: Is aTyr Pharma Inc. exposed to political riskJuly 2025 Snapshot & Weekly Stock Performance Updates - خودرو بانک
What data driven models say about aTyr Pharma Inc.’s futureProfit Target & Fast Moving Trade Plans - Newser
Visualizing aTyr Pharma Inc. stock with heatmaps2025 Top Decliners & Safe Capital Growth Tips - Newser
Using fundamentals and technicals on aTyr Pharma Inc.Portfolio Value Report & Weekly Momentum Picks - Newser
aTyr Pharma Inc.’s volatility index tracking explainedWeekly Trend Summary & Real-Time Stock Movement Alerts - Newser
Will breakout in aTyr Pharma Inc. lead to full recoveryJuly 2025 Setups & Safe Capital Growth Stock Tips - Newser
aTyr Pharma’s Sharp Intraday Drop: What’s Behind the Move? - AInvest
Volatility clustering patterns for aTyr Pharma Inc.July 2025 PreEarnings & AI Enhanced Trade Execution Alerts - Newser
Heatmap analysis for aTyr Pharma Inc. and competitors2025 Risk Factors & Long-Term Growth Portfolio Plans - Newser
Aug Rallies: Is aTyr Pharma Inc.’s ROE strong enoughInsider Buying & Community Verified Trade Signals - خودرو بانک
Is aTyr Pharma Inc. exposed to political riskMarket Risk Report & Daily Growth Stock Investment Tips - خودرو بانک
aTyr Pharma Inc. recovery potential after sell off2025 Trade Ideas & Stepwise Trade Signal Implementation - Newser
Atyr Pharma Inc Stock (ATYR) Financials Data
There is no financial data for Atyr Pharma Inc (ATYR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):